Carole Mitnick, ScD discusses the impact of the endTB trial's findings on future TB treatment options, including shorter treatment durations, lower costs, and expanded accessibility.
Carole Mitnick, ScD
Advertisement
Professor at Harvard Medical School and Senior Research Associate at Partners in Health.
Articles by Carole Mitnick, ScD
Carole Mitnick, ScD highlights the importance of trust in the success of the endTB trial and addresses the ongoing toxicity concerns with new shorter treatment regimens.
Advertisement
Latest Updated Articles
Five All-Oral Regimens Show Efficacy in the Phase 3 endTB Trial for Rifampin-Resistant TBPublished: February 10th 2025 | Updated:
Advertisement
Advertisement
Trending on Contagion Live
1
Higher Acceptability of 1 Injectable in First Head-to-Head Comparison of Long-Acting PrEP
2
One Third of Chronic Hepatitis B Patients Are Lost to Follow-Up
3
Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Post-Antibiotic Era
4
